Preclinical and clinical properties of elbasvir (ERELSA® Tablets 50 mg) and Grazoprevir (GRAZYNA® Tablets 50 mg), novel therapeutic agents for hepatitis C
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.